StockData

RxSight vs Sanara MedTech

RXST and SMTI side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RXST and SMTI compare

Sanara MedTech is the larger company, worth 1.5 times as much as RxSight ($301M against $201M).

Sanara MedTech grew revenue faster over the last twelve months (13.0% versus −13.2% for RxSight).

Sanara MedTech keeps more of each dollar of sales as profit, with a net margin of −29.2% compared with −36.8% at RxSight.

RxSight scores higher on the StockData Score (10 against 6 for Sanara MedTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRXSTSMTI
Size and price
Market cap$201M$301M
Share price$4.83$32.73
Change, 1 year−50.4%51.9%
Change, 5 years−61.0%14.2%
Beta (5Y)1.331.43
Employees461108
StockData Score
Total score10 (better)6
Valuation score3 (better)0
Growth score23 (better)
Performance score11
Health score4 (better)2
Dividend score00
Valuation
P/S1.6× (better)2.7×
P/B0.8× (better)37.9×
EV/EBITDA–30.4×
P/FCF–66.8×
FCF yield−13.5%1.5% (better)
Fair value$20.39$13.42
Margin of safety76.3% (better)−144%
Growth
Revenue growth (TTM)−13.2%13.0% (better)
Revenue growth, 5Y average55.7% (better)45.9%
Profitability
Gross margin77.5%93.0% (better)
Operating margin−43.2%7.7% (better)
Net margin−36.8%−29.2% (better)
FCF margin−21.3%4.1% (better)
Return on equity−17.3% (better)−148%
Return on invested capital−82.9%13.1% (better)
Financial health
Debt / equity0.005.85 (better)
Net debt / EBITDA–2.85
Interest coverage−3674.3×1.2× (better)
Current ratio4.07 (better)2.58
Altman Z-score−0.703.76 (better)
Piotroski F-score33
Dividends and buybacks
Buyback yield−1.00%–
Shareholder yield−1.00%0.00% (better)
Ownership
Held by institutions99.6%19.4%
Held by insiders5.4%14.9%
Insider net buying, 12 months−$118K–
Short interest, % of float9.2%5.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.